Repeat Mitral Valve Replacement: 30-Years’ Experience

Victor Expósito,a Tamara García-Camarero,a José M. Bernal,b Elena Arnáiz,b Aurelio Sarralde,b Iván García,b José R. Berrazueta,a and José M. Revuetab

aServicio de Cardiología, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria. Santander, Cantabria, Spain.
bServicio de Cirugía Cardiovascular, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Santander, Cantabria. Spain.

Prosthetic heart valve dysfunction is an acquired condition that carries a significant risk of emergency surgery. However, the long-term natural history of the condition is not well understood. Between 1974 and 2006, 1535 isolated mitral valve replacements were performed at our hospital (in-hospital mortality 5%). In total, 369 patients needed a second operation (in-hospital mortality 8.1%), while 80 (age 59.8 ± 11.4 years) needed a third. The reasons for the third intervention were structural deterioration (67.5%), paravalvular leak (20%), and endocarditis (6.3%). Some 15 patients died in hospital (18.8%). After a mean follow-up period of 17.8 years, 21 patients needed another intervention (ie, a fourth intervention). The actuarial reoperation-free rate at 20 years was 40.1% ± 13.8%. The late mortality rate was 58.5% (18-year survival rate 15.4% ± 5.4%). Indications for repeat mitral valve replacement must be judged on an individual basis given the high risk associated with surgery.

Key words: Valvular reoperation. Mitral valve dysfunction. Repeat valvular surgery.

INTRODUCTION

The mortality associated with repeat valve repair is 4.7% to 6.8% for scheduled surgery1,2 and as high as 25% to 41% for emergency reoperations, as in the case of prosthetic heart valve thrombosis.3 However, the long-term natural history of patients who require various reoperations for prosthetic mitral valve dysfunction is not well understood. The purpose of this retrospective study is to analyze the early and long-term outcome of patients who require repeat operations for prosthetic mitral valve dysfunction.

METHODS

Between 1974 and 2006, 1535 isolated mitral valve replacements (MVR) were performed in our hospital (879 bioprosthetic, 656 mechanical). The mean age of patients at the time of the first operation was 56.2 (13.9) years and the causes were rheumatic valve disease (57.7%), degenerative disease (35.9%), or other (6.4%). The in-hospital mortality in this group was 5% (cardiac, 50; infectious, 7; respiratory, 3; renal, 2; hemorrhagic, 5; neurologic, 3). During follow-up, 369 (24%) patients required a second MVR operation (119 bioprosthetic, 250...
The procedures were associated with aortic valve replacement in 12 and tricuspid valve annuloplasty in 16.

Follow-up

Follow-up was handled by the outpatient service and by contact with the patients or their relatives. The information was completed by contacting the hospitals and consulting the databases of the health services of the various autonomous communities of origin, the admission and clinical documentation services, and in some cases, the health centers. All patients were followed up after the third operation, although 2 patients were lost to follow-up at 7.8 and 14.2 years. The maximum follow-up possible was 5398 months and the actual follow-up obtained was 5306 months; hence, the follow-up was complete at 98.3%, with a mean follow-up of 17.8 (range, 2-32) years.

Statistical Analysis

The values are expressed as the mean (SD). The Student t test was used to compare quantitative variables, and survival and event-free curves were calculated using the actuarial method. Stata Intercooled, version 6 (Stata Corporation, College Station, Texas, United States), was used for the statistical calculations.

RESULTS

In-hospital Mortality

Fifteen patients died in hospital (18.8%) after the third operation. This figure is statistically significant (P<.05) when compared to the in-hospital mortality.
of the first and the second operation (5% and 8.1%, respectively). The cause of death was cardiac in 8 patients, hemorrhagic in 3, infectious in 2, and neurologic in 2. Late mortality comprised 38 (58.5%) deaths, mainly cardiovascular (35 patients), including 8 in successive reoperations; 2 were due to cancer and 1 to a traffic accident. In-hospital mortality was 17.8% and late mortality 55.4% when the lesion was structural deterioration of a bioprosthesis, and 14.3% (nonsignificant) and 61.9% ($P=.07$) when the etiology was annular disease (endocarditis or valvular leak). The actuarial survival rate was 40.7% (5.7%) at 6 years, 24.6% (5.4%) at 12 years, and 15.4% (5.4%) at 18 years (Figure 1).

**DISCUSSION**

Prosthetic valve dysfunction is an acquired condition that presents in up to 10% of patients after the first MVR. A decrease in early mortality from 7%-20% to 4%-5% has been reported in recent publications. The long-term natural history, however, is not well defined. Nonetheless, it is understood that the outcome for patients with repeat

**Subsequent Reoperations**

Of the 65 survivors, 19 (29.2%) required a fourth mitral operation, 42.1% for structural deterioration, 42.1% for paravalvular leak, and 15.8% for endocarditis; in-hospital mortality was 42.1% and late mortality 26.3%. The actuarial reoperation-free rate (Figure 2) was 65.8% (6.8%) at 6 years, 50.3% (10.9%) at 14 years, and 40.1% (13.8%) at 20 years. A statistically significant relationship was observed between the need for reoperation and etiology. New reoperations were required for structural deterioration of the bioprosthesis in 21.4%, and for annular disease (endocarditis or valvular leak) in 42.9% ($P=.035$).
reoperations is not necessarily satisfactory.\textsuperscript{3} The
literature on repeat reoperations is scanty and often
mixes several types of reoperations. The main reason
for the initial reoperation for prosthetic dysfunction
is structural deterioration of the bioprosthesis.
The widespread use of bioprostheses in our series
can be explained by the difficulties encountered to
ensure adequate anticoagulation in our population
during the earlier years of this experience.\textsuperscript{4} Repeat
replacements were associated with high mortality
in our experience, with early mortality at 18.8% and
late mortality at 58.5% over a mean follow-up of
18 years. Certain approach routes, such as left
thoracotomy or the Heart Port technique, can help
reduce high early mortality. In addition, 19 patients
required a fourth operation, with an actuarial
reoperation rate of 40% at 16 years. The risk in
the first elective reoperation is low and, therefore,
the indication of bioprosthesis has been extended
to populations of young patients.\textsuperscript{3} However,
in-hospital mortality progressively increases with each
new reoperation. This study showed that the mean
age of the patient groups was very similar in the
successive operations, likely because the durability
of the bioprosthesis is lower in young patients and in
the mitral position, as we have reported previously.\textsuperscript{5}
In subsequent reoperations, annulus involvement
(endocarditis or valvular leak) gradually becomes
more important than the structural deterioration
of the bioprosthesis, and is associated with higher
mortality. In conclusion, repeat prosthetic mitral
valve dysfunction has a poor early and late
prognosis and high associated mortality. Annular
disease (valvular leak or endocarditis) results in a
high incidence of reoperations. The indication for
a repeat valve surgery should be assessed on an
individual basis because the associated surgical risk
is very high.

REFERENCES

1. Akins CW, Buckley MJ, Daggett WM, Hilgenberg AD,
   Vlahakes GJ, Torchiana DF, et al. Risk of reoperative valve
   replacement for failed mitral and aortic bioprostheses. Ann
2. Potter DD, Sundt TM, Zehr KJ, Dearani JA, Daly RC,
   Mullany CJ, et al. Risk of repeat mitral valve replacement for
   72.
3. Antunes MJ. Reoperations on cardiac valves. J Heart Valve
4. Echevarría JR, Bernal JM, Rabasa JM, Morales D, Revilla
   Y, Revuelta JM. Reoperation for bioprosthetic valve
5. Bernal JM, Rabasa JM, López R, Niscal F, Muñiz R,
   Revuelta JM. Durability of the Carpentier-Edwards porcine
   bioprosthesis. Role of age and valve position. Ann Thorac